AlfieWinter 2022Acquired☆Watch⊞Compare

AI analyst read est. — model-extracted from this company's public description, not a verified fact. 30%

operates a technology-led product inferred from public copy

Grounded in: “You are a venture analyst”

Democratizing access to precision weight loss medications

At Alfie, we've built a rigorous virtual medical program based on the top research from Cleveland Clinic and Harvard that allows us to precisely determine which weight loss regimen and (as needed) medications will be most effective for our members in a multimodal approach. We're optimizing exercise/nutrition/medications in complex care pathways like no one else has before. Our program has been shown to be 2x more effective than standard prescription medication and 5x more effective than habit change alone. We've raised capital from Goodwater Capital, Nina Capital, Air Force Ventures, and Phoenix Club, and various super angels including the founder of OpenTrons (medical labs automation; have raised $240 mill). Also, we're a Y Combinator graduate.

As reported in public records reported — not modeled.

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

No round amounts on record to chart.

No staged rounds to sequence.

Round size and date are reported; the stage label is inferred from round size. Valuation is modeled from stage benchmarks. Directional, not a quoted figure.

Not enough modeled valuation points to chart a trajectory.

Benchmarked against 8525 companies in this sector. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Raised more than 96% of sector peers (real $). Modeled value above 96% of peers (estimate).

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Alfie is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

See where Alfie sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

If you work at Alfie, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.